|
|
|
|
|
|
|
23.12.25 - 08:36
|
Scope revises Corem′s credit rating to BB+ with stable outlook (Cision)
|
|
|
Scope Ratings has revised Corem's credit rating, resulting in a downgrade from the previous BBB- with a negative outlook to BB+ with a stable outlook. The report is based on third-quarter results and thereafter published information. Reasons for the change mention potential risks related to the average vacancy rate of the portfolio following made divestments and the current interest coverage ratio.
“The areas which are highlighted as positive drivers in the rating align well with the strategy we have set going forward. We remain confident in the leasing opportunities ahead, and our...
|
|
|
23.12.25 - 08:36
|
Dynavox Group to acquire SR Labs Healthcare in Italy (Cision)
|
|
|
Dynavox Group AB (publ), the parent company of Tobii Dynavox and the global leader in assistive communication, has entered into an agreement to acquire all shares of its Italian reselling partner, SR Labs Healthcare. This strategic move will strengthen Tobii Dynavox's presence in southern Europe and enhance its ability to support individuals with communication disabilities. The transaction is expected to close during the first half of 2026.
Headquartered in Milan, SR Labs is a leading provider of assistive communication technologies and services throughout Italy. Since its founding in...
|
|
|
23.12.25 - 08:36
|
Qlife provides end-year operational update on key issues (Cision)
|
|
|
Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, provides a year-end operational update on key issues.
Diabetes data
Egoo Health has achieved breakthrough precision in key diabetes biomarker test. The Egoo HbA1c blood test for diabetes management has achieved best-in-class precision with a coefficient of variation (CV) below 3%. This achievement positions Egoo as potentially the first home-use HbA1c test to meet the same stringent clinical and regulatory standards. The diabetes diagnostics market, with a focus on moving clinical diabetes...
|
|
|
23.12.25 - 08:36
|
BTC AB carries out a directed issue of Preference A shares of approx. SEK 7.2 million (Cision)
|
|
|
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE, JAPAN, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD NOT BE IN COMPLIANCE WITH APPLICABLE LAWS OR REGULATIONS OR WOULD REQUIRE REGISTRATION OR SIMILAR MEASURES. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE.
The Board of Directors of B Treasury Capital AB (“BTC AB” or the “Company”) has today, based on the...
|
|
|
23.12.25 - 08:36
|
Repurchases of shares in Betsson during week 51 (Cision)
|
|
|
Between 15 December and 19 December 2025, Betsson AB (publ) (“Betsson”) has repurchased in total 125,100 own series B shares (ISIN: SE0022726485) as part of the share buyback program initiated by the Board of Directors on 24 October 2025.
The share repurchases form part of Betsson's share buyback program of up to the equivalent of EUR 40 million, as announced by Betsson on 24 October 2025. The buyback program runs from 24 October 2025 to 30 April 2026 and is being carried out in accordance with the EU Market Abuse Regulation (MAR) and the Commission Delegated Regulation (EU) 2016/...
|
|
|
23.12.25 - 08:36
|
Sanofi Neutral (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sanofi auf "Neutral" belassen. Die Vereinbarungen zwischen europäischen Pharmakonzernen wie GSK, Novartis, Roche und Sanofi mit der US-Regierung über tiefere Medikamentenpreise ......
|
|
|
23.12.25 - 08:36
|
Roche Neutral (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Roche auf "Neutral" belassen. Die Vereinbarungen zwischen europäischen Pharmakonzernen wie GSK, Novartis, Roche und Sanofi mit der US-Regierung über tiefere Medikamentenpreise in ......
|
|
|
23.12.25 - 08:36
|
GSK Underweight (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK auf "Underweight" belassen. Die Vereinbarungen zwischen europäischen Pharmakonzernen wie GSK, Novartis, Roche und Sanofi mit der US-Regierung über tiefere Medikamentenpreise ......
|
|
|
23.12.25 - 08:36
|
Novartis Overweight (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Novartis auf "Overweight" belassen. Die Vereinbarungen zwischen europäischen Pharmakonzernen wie GSK, Novartis, Roche und Sanofi mit der US-Regierung über tiefere Medikamentenpreise ......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.12.25 - 08:30
|
Europe Car Sales Increase In November (AFX)
|
|
|
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Europe's new car registrations increased for the fifth straight month in November, driven by robust growth in battery electric cars sales, data from the Europe......
|
|
|
23.12.25 - 08:30
|
Nucera-Aktie: Kommt 2026 der Aufschwung? (Sharedeals)
|
|
|
Die Aktie von ThyssenKrupp Nucera konnte sich von dem Kurseinbruch im Oktober und November teilweise wieder erholen. Das Tief lag Ende November bei 7,50 €. Am Dienstag gewinnt sie aktuell leicht und steht bei 9,20 €. Was ist hier zu erwarten? Wenig Optimismus Nachdem das abgelaufene Geschäftsjahr zufriedenstellend ausfiel, ist das Unternehmen für das laufende […]
The post Nucera-Aktie: Kommt 2026 der Aufschwung? first appeared on sharedeals.de....
|
|
|
|
Alle News zu Europa 5743.55 -0.07% (E.St.50 Kurs)
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
